This website is intended for UK healthcare professionals only. Not a UK healthcare professional? Click here.

Prescribing Information and Adverse Event Reporting (links to external website):

NILEMDO®

NUSTENDI®

  • Home
  • Lipid management

Lipid management

Lipid-lowering therapy forms a cornerstone of CV risk management1

High LDL-C is one of the key modifiable CVD risk factors.2–4

Aim for the lowest LDL-C possible as early as possible to reduce CV risk in your patients with high and very-high CV risk.5

Concomitant use of NILEMDO®/NUSTENDI® with simvastatin >40 mg daily is contraindicated; please refer to the relevant SmPC for more information.6,7

Statin therapy alone can be insufficient to lower LDL-C levels to target10

When the dose of a statin is doubled, there is a 4–6% increase in LDL-C lowering efficacy.11,*

70% of patients on LLT monotherapy in the SANTORINI study did not achieve their LDL-C target, leaving them at risk of CVD13,†


†Prospective, observational, non-interventional study of patients with high and very high ASCVD risk across Europe (Europe N=9,602; UK n=673). Patients eligible for enrolment were ≥18 years of age with high or very high risk of ASCVD, for whom LLT would likely be beneficial and had an anticipated life expectancy of more than one year. 20.2% of enrolled patients in the UK did not receive any LLT; 75.6% of patients received monotherapy; and 4.0% of patients received combination LLT.13

Guidance Next

References

  1. Samarasekera EJ, et al. BMJ. 2023;381:p1028.
  2. British Heart Foundation. UK Factsheet. 2024. Available at: https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-uk-factsheet.pdf Accessed: February 2025.
  3. Fox KM, et al. Clin Res Cardiol. 2018;107(5):380–388.
  4. Duncan MS, et al. J Am Heart Assoc. 2019;8(11):e011433.
  5. Averna M, et al. Atherosclerosis. 2021;325:99–109.
  6. NILEMDO® Summary of Product Characteristics.
  7. NUSTENDI® Summary of Product Characteristics.
  8. Ference BA, et al. Eur Heart J. 2018;39:2540–2545.
  9. Pfizer. Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor 1 November 2016. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor Accessed: February 2025.
  10. Krähenbühl S, et al. Drugs. 2016;76(12):1175–1190.
  11. Nicholls SJ, et al. Am J Cardiol. 2010;105(1):69–76. 
  12. NHS England. Summary of national guidance for lipid management. April 2024. Available at: https://www.england.nhs.uk/aac/publication/summary-of-national-guidance-for-lipid-management/ Accessed: February 2025.
  13. Ray KK, et al. Lancet Reg Health Eur. 2023;29:100624.

Abbreviations


AAC, Accelerated Access Collaborative; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy. NHS, National Health Service; PCSK9; proprotein convertase subtilisin/kexin type 9; SmPC, Summary of Product Characteristics; UK, United Kingdom.

Job code: UK/BIL/11/24/0006|Date of preparation: February 2025

Job code: UK/BIL/11/24/0003|Date of preparation: February 2025

All rights reserved. © Daiichi Sankyo UK Limited. Company No: 01998736

You are now leaving this website

Please note that our terms of use (especially those mentioned under "Terms and Conditions") are no longer valid as soon as you click on the "Continue" button. As we do not have any influence on linked websites, we assume no liability for their content or use. If you would like to return to our website, please click the "Return" button.

Job code: UK/BIL/11/24/0015 | Date of preparation: February 2025

This is a Daiichi Sankyo site intended for UK healthcare professionals (HCPs) and other relevant decision makers,* where you can find promotional information about Daiichi Sankyo products and professional resources.

So that we can provide you with the most appropriate information, please choose one of the following options:

I am a UK healthcare professional

This website contains promotional information intended for UK healthcare professionals and other relevant decision makers only.

Confirm
I am a member of the public

This website provides members of the UK public with details about Daiichi Sankyo and its medicines. For further information about your health or medicines please consult your doctor, nurse or pharmacist.

Confirm

*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply, or use of any medicine but who are not healthcare professionals.

Job code: UK/BIL/11/24/0002 | Date of preparation: February 2025

All rights reserved. © Daiichi Sankyo UK Limited. Company No: 01998736